Helene Hartvedt Grytli
Position: Post.Doc
Phone: +47 22 78 23 13
Email:
 

Author network for Helene Hartvedt Grytli by COREMINE medical


Publications 2016

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mćlandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-94
PubMed 26646591

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang WZ, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Maelandsmo GM, Svindland A, Barbier O, Tasken KA (2016)
Low beta(2)-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-1894

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skĺlhegg BS (2016)
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
Urol Oncol, 35 (3), 111.e1-111.e8
PubMed 27838142

Ramberg H, Grytli HH, Nygĺrd S, Wang W, Ögren O, Zhao S, Lřvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA (2016)
PBX3 is a putative biomarker of aggressive prostate cancer
Int J Cancer, 139 (8), 1810-20
PubMed 27273830

Publications 2014

Braadland PR, Ramberg H, Grytli HH, Taskén KA (2014)
β-Adrenergic Receptor Signaling in Prostate Cancer
Front Oncol, 4, 375
PubMed 25629002

Publications 2013

Grytli HH, Fagerland MW, Fossĺ SD, Taskén KA (2013)
Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease
Eur Urol, 65 (3), 635-41
PubMed 23351721

Grytli HH, Fagerland MW, Fossĺ SD, Taskén KA (2013)
Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's letter to the editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fossĺ, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007
Eur Urol, 64 (1), e11-2
PubMed 23602404

Publications 2012

Grytli HH, Fagerland MW, Fossĺ SD, Taskén KA, Hĺheim LL (2012)
Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy
Prostate, 73 (3), 250-60
PubMed 22821802